A bioengineer who learned to sell, a consultant who learned to build. Now he runs the business at Salt AI - where biology and software finally share a room.
Nate Beyor sells trust. The product happens to be AI for people inventing medicines.
At Salt AI, the Los Angeles company building contextual AI for life sciences and healthcare, Beyor is the Chief Business Officer - the person who turns a research platform into deals, strategy, and a path into regulated labs. He joined in 2025 as the company expanded its leadership bench right after a $10M raise, brought in specifically to drive its push into drug discovery and biotech.
His job is deceptively simple to describe and hard to do: help translational scientists and drug developers move faster with AI they can actually rely on. In a hospital or a clinical pipeline, "move fast and break things" is not a slogan - it's a lawsuit. So Beyor sits where the science, the software, and the regulation all collide, and he makes them agree.
What makes him the right fit isn't a sales background. It's that he has actually done the science. He has built the chips, licensed the IP, manufactured the biologics, and advised the boards. He's seen the work from nearly every chair in the building - which is exactly why he's allergic to bolting technology onto broken processes.
That breadth is rarer than it sounds. Most people who can read a clinical protocol can't read a term sheet, and most people who can negotiate IP licensing have never stood at a lab bench. Beyor has done both, and the in-between, and it shows in how he talks about the field - less as a pitch, more as a tour given by someone who knows where the load-bearing walls are. When he says AI should serve translational scientists, it lands differently because he has been the scientist waiting on a slow result.
"Build first. You'll learn more by trying to do it than you will by spending a year debating what to do."- Nate Beyor
Ask most people about digital transformation and they'll list tools. Beyor flips it. The point, he argues, isn't to sprinkle software on top of yesterday's process - it's to transform the process itself, then automate or delete the parts that never needed a human in the first place.
His twin obsessions are data connectivity and interoperability, the unglamorous plumbing that lets one system talk to another. Get that right, and automation compounds. Outcomes improve. He's comfortable letting algorithms make recommendations as a safer path - while keeping a human firmly on the final decision. Trust, not novelty, is the metric.
It's a worldview earned the hard way, across remote monitoring, clinical technology, supply chain, and precision medicine. He's launched these things, not just slide-decked them.
There's a quiet radicalism in that stance. Plenty of executives sell automation as a way to do the same job with fewer people. Beyor's framing is different and more uncomfortable: if a step can be eliminated, eliminate it; if a decision can be made more safely by an algorithm, let the algorithm make it - then hand the human the part only a human should own. The goal isn't a faster version of the old workflow. It's a workflow that wouldn't recognize its former self.
He has worked nearly every layer of the life-sciences stack - and never once left the seam where the two disciplines meet.
His doctoral work: tiny channels engineered to catch pathogens. The literal chips behind the career.
At Asterias Biotherapeutics, he ran corporate development for cutting-edge cell therapy - deals, licensing, strategy.
From manufacturing to remote monitoring and clintech, launching digital solutions across care delivery.
Led BCG's Health Tech practice, pulling tech-native companies into healthcare and life sciences.
Hands-on with supply chain, precision medicine, and the data plumbing that makes them work together.
Now at Salt AI, aiming the whole platform at protein generation, biomarker discovery, and drug development.
Salt AI is a Los Angeles company founded by veterans of high-performance computing and AI - CEO Aber Whitcomb and CTO Jim Benedetto. Its pitch is contextual, transparent AI for regulated enterprise teams, with the unglamorous virtues that matter in a lab: data sovereignty, multi-model orchestration, and a visual-first interface that takes a project from prototype to production.
The mission Beyor signed up for: help translational scientists and drug developers accelerate discovery using intelligent, adaptive systems - protein generation, biomarker discovery, clinical evidence synthesis - without sacrificing the trust regulated work demands.
As CEO Aber Whitcomb put it, "Delivering real AI value in life sciences depends on pairing a world-class technology backbone with a deep understanding of the science itself." That second half is Beyor's whole résumé.
Beyor doesn't hide behind a corporate wall. He shows up - at SXSW, at CES, on podcasts aimed squarely at people building in health and life sciences. On the Life Sciences Today podcast in 2025, he walked through how Salt AI's platform creates value for researchers, how the company captures value from its partnerships, and what he wants to see in the next 12 to 18 months. On the DTx podcast, the subject was teams and products: how you actually take a digital therapeutic to market, not in theory but in the messy reality of building.
The thread across all of it is the same pragmatism. He's interested in ecosystems, in the unglamorous work of getting systems to talk to each other, and in the difference between a demo and a deployment. He'd rather show a working thing than promise a perfect one - which is, not coincidentally, exactly the advice he gives anyone who'll listen.
Look at the resume sideways and a pattern appears. Microfluidics was a bet that you could engineer biology at small scale. Stem-cell corporate development was a bet that you could build a business around therapies that barely existed yet. Health Tech at BCG was a bet that the tech world and the medicine world needed a translator. Salt AI is the same bet, placed once more: that biology and software belong in the same room, and that the people who can stand comfortably in both are the ones who'll move the field.
Beyor has spent two decades refusing to specialize all the way down. That looks like indecision until you notice he's been answering the same question the whole time - how do you make powerful technology actually useful to the people inventing medicines? - and just kept moving to wherever the answer was being written. First the lab. Then the deal table. Then the boardroom. Now the company.
It's a career that rewards the long view, which is fitting for a man whose advice is to start before you're ready. The debate, he'd remind you, teaches you less than the doing. He's been doing it since the chips were made of glass.